CCDC88C::PDGFRB-Rearranged Myeloid Neoplasm with Predominant Neutrophilia and Rapid Response to Imatinib: A Molecularly Defined Case Report - Top-Institutions - MDSpire

CCDC88C::PDGFRB-Rearranged Myeloid Neoplasm with Predominant Neutrophilia and Rapid Response to Imatinib: A Molecularly Defined Case Report

  • By

  • Guo, Yafei

  • Wu, Huiqiang

  • Cai, Zhiyin

  • Chen, Genwang

  • Meiling, Li

  • Guo, Xizhe

  • June 22, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Hematology
    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Hematology
    • Oncology

  • #3

    Mayo Clinic Rochester
    Mayo Clinic Rochester

    Rochester, Minnesota

    Key Differentiators

    • Hematology
    • Oncology

  • #4

    MLL Munich Leukemia Laboratory
    MLL Munich Leukemia Laboratory

    Munich, Bavaria

    Key Differentiators

    • Hematology
    • Laboratory Medicine

  • #5

    National Cancer Institute
    National Cancer Institute

    Rio de Janeiro, Brazil

    Key Differentiators

    • Hematology
    • Oncology

Original Source(s)

CCDC88C::PDGFRB-Rearranged Myeloid Neoplasm with Predominant Neutrophilia and Rapid Response to Imatinib: A Molecularly Defined Case Report

  • by Guo, Yafei , Wu, Huiqiang , Cai, Zhiyin , Chen, Genwang , Meiling, Li , Guo, Xizhe

  • June 22, 2026

Related Content

Liquid Biopsy in Pediatric Acute Lymphoblastic Leukemia (ALL)

NOSIP overexpression promotes long-term persistence of CD8+ T cells during chronic infection

A screening model for advanced colorectal neoplasia based on tumor markers and inflammatory indices: a retrospective study with an online risk calculator